Pfizer raises COVID-19 vaccine sales forecast to $36 billion -Breaking
[ad_1]
© Reuters. FILEPHOTO: In this illustration, a vial and a needle are shown at the Pfizer logo. It was taken June 24, 2021. REUTERS/Dado Ruvic/Illustration/File Photo (Reuters) – Pfizer Inc (NYSE) Tuesday increased its full-year forecast for COVID-19 vaccine sales by 7.5%, to $36 Billion. It signed deals with other countries and received clearances for use of its shots in children.
In July, the company forecasted sales of $33.5 million from its vaccine with BioNTech.
Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.
Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.
[ad_2]